Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.43

+3.8%
HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

At a Glance

Live Snapshot
Market Cap$159.68M
EPS-1.6700
P/E Ratio-4.45
Earnings Date08/13/2026

uncy

Operating Expenses

Last Annual Value

28.95M

3-Year CAGR

15%

5-Year CAGR

70%

10-Year CAGR

41%

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Competitors Analysis of Operating Expenses

UNCY · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
28.95M
10.5%26.4%N/A 
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
219.18M
36.5%54.5%19.7%
CBUS logo
Cibus, Inc.
NASDAQ:CBUS
65.18M
-41.2%19.5%18.1%
112.56M
-18.0%-13.0%4.7%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
7.39M
8.8%10.8%47.5%
IMA logo
ImageneBio Inc
NASDAQ:IMA
48.22M
-16.7%21.8%N/A
48.84M
-18.3%-7.9%N/A
86.21M
3.0%8.6%N/A
25.74M
-11.5%10.4%31.5%
82.76M
7.5%38.6%N/A
79.90M
-14.1%13.9%N/A
Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.43, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

Intrinsic Value
Current Price: $7.43